Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shenzhen Stock Exchange
  5. Hualan Biological Engineering Inc.
  6. Summary
    002007   CNE000001JN8

HUALAN BIOLOGICAL ENGINEERING INC.

(002007)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Shenzhen Stock Exchange
10/11/2021 10/12/2021 10/13/2021 10/14/2021 10/15/2021 Date
28.75 29.29 30.37 30.6 29.8 Last
17034320 26660920 27385430 30226070 19894460 Volume
+0.70% +1.88% +3.69% +0.76% -2.61% Change
Estimated financial data (e)
Sales 2021 5 780 M 898 M 898 M
Net income 2021 1 833 M 285 M 285 M
Net cash position 2021 1 935 M 301 M 301 M
P/E ratio 2021 29,6x
Yield 2021 1,24%
Sales 2022 7 082 M 1 101 M 1 101 M
Net income 2022 2 282 M 355 M 355 M
Net cash position 2022 2 266 M 352 M 352 M
P/E ratio 2022 23,7x
Yield 2022 1,53%
Capitalization 54 366 M 8 449 M 8 450 M
EV / Sales 2021 9,07x
EV / Sales 2022 7,36x
Nbr of Employees 2 887
Free-Float 52,7%
More Financials
Company
HUALAN BIOLOGICAL ENGINEERING, INC. is a China-based company principally engaged in the research, development, production and sales of blood products. It also produces vaccine products and biological engineering products. The Company's main products include human albumins, human immunoglobulin for intravenous injection, human immunoglobulin, human coagulation factors, human rabies immunoglobulin, human tetanus... 
More about the company
Ratings of Hualan Biological Engineering Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about HUALAN BIOLOGICAL ENGINEERING INC.
08/29Hualan Biological Engineering Inc. Reports Earnings Results for the Half Year Ended Jun..
CI
06/16Hualan Biological Engineering Inc. Announces Final Cash Dividend on A Shares for the Ye..
CI
04/29Hualan Biological Engineering Inc. Reports Earnings Results for the First Quarter Ended..
CI
04/20HUALAN BIOLOGICAL ENGINEERING : to Produce Russia's Sputnik COVID-19 Vaccine in China
MT
03/30Hualan Biological Engineering Inc. Proposes Final Dividend for 2020
CI
03/17Hualan Biological Engineering Inc. Reports Earnings Results for the Full Year Ended Dec..
CI
2020LG shakes up loss-making phone business, to outsource lower-end models
RE
2020Samsung may discontinue high-end Galaxy Note smartphones - sources
RE
2020Hualan Biological Engineering Inc. Reports Earnings Results for the Nine Months Ended S..
CI
2020Samsung Electronics profit likely at two-year high after Huawei orders, phone recovery
RE
2020Samsung Elec profit likely at 2-year high after Huawei orders, phone recovery
RE
2020Hualan Biological Engineering Inc. Reports Earnings Results for the Half Year Ended Jun..
CI
2020Verdict in first 1MDB case packs risk for Malaysian government
RE
2020Hualan Biological Engineering Plans to List Vaccine Unit on Shenzhen Chinext Board
CI
2020Hualan Biological Engineering Inc. Approves Cash Dividend for the Year 2019, Payable on..
CI
More news
News in other languages on HUALAN BIOLOGICAL ENGINEERING INC.
2020Kretschmann mahnt einheitliches Vorgehen bei Fan-Frage an
2020BVB-Profi Delaney sieht Dänemark bei Fan-Rückkehr als Vorbild
2020En Chine, 182 nouveaux milliardaires en un an
More news
Chart HUALAN BIOLOGICAL ENGINEERING INC.
Duration : Period :
Hualan Biological Engineering Inc. Technical Analysis Chart | 002007 | CNE000001JN8 | MarketScreener
Technical analysis trends HUALAN BIOLOGICAL ENGINEERING INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Last Close Price 29,80 CNY
Average target price 40,50 CNY
Spread / Average Target 35,9%
EPS Revisions
Managers and Directors
Kang An Chairman & General Manager
Jun Min Xie Chief Financial Officer & Board Secretary
Chao Yuan Ma Chairman-Supervisory Board
Pei Tang Huang Independent Director
Yun Long Wang Independent Director
Sector and Competitors
1st jan.Capi. (M$)
HUALAN BIOLOGICAL ENGINEERING INC.-29.45%8 449
GILEAD SCIENCES, INC.16.08%84 795
WUXI APPTEC CO., LTD.29.45%66 184
BIONTECH SE203.83%59 820
REGENERON PHARMACEUTICALS14.52%57 519
VERTEX PHARMACEUTICALS-23.09%47 156